Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients
The prevalence of peripheral neuropathy (PNP) during the treatment of MM with Bortezomib is high.
About 20% of patients develop a grade 3-4 PNP due to this treatment, and as a result Bortezomib treatment is
stopped or a reduced dose is given. Therefore, there is a strong need to find markers which predict the
susceptibility of a patient to develop Bortezomib related PNP.
Click the PDF tab to view and dowload the document